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Abstract
We have developed a noninvasive magnetic resonance
imaging (MRI) assay to characterize human umbilical
vein endothelial cell (HUVEC)motility, invasion, and net-
work formation in response to the presence of cancer
cells. HUVECs were labeled with a superparamagnetic
iron oxide T2 contrast agent and cocultured with MDA-
MB-231 breast cancer cells in the presence of an extra-
cellular matrix (ECM) gel. Invasion into the ECM gel by
HUVECs in response to paracrine factors secreted by
MDA-MB-231 cancer cells, as well as network forma-
tion by HUVECs, was easily tracked with MRI. The in-
vasive behavior of HUVECs was not observed in the
absence of cancer cells. This noninvasive assay used
to characterize the response of endothelial cells (ECs)
can be used to understand the role of proangiogenic
or antiangiogenic stimuli, and to study the interactions
between ECs and other disease-specific cells in pathol-
ogies with aberrant angiogenesis, such as retinopathy
and arthritis.
Neoplasia (2006) 8, 207–213
Keywords: Invasion, iron oxide, endothelial cells, magnetic resonance, cell
tracking.
Introduction
Evaluation of the role of angiogenesis in cancer, as well as
the identification of suitable antiangiogenic therapies,
requires a thorough understanding of endothelial cell (EC)
response to angiogenic-promoting or angiogenic-inhibiting
factors or to antiangiogenic drugs. The induction of angio-
genesis is regulated by a balance of numerous proangio-
genic and antiangiogenic factors [1,2]. Cytokines and
growth factors secreted by tumor cells induce paracrine
loops that result in EC activation. Nondestructive assays
are necessary to further understand the role of these fac-
tors in EC survival, motility, invasive potential, and tubulo-
genesis in systems that can mimic, to some extent, cancer
cell/EC interactions that occur in or around tumors, under
carefully controlled conditions. Previous studies have
reported the design of assays to characterize the relation-
ship between cancer cells and ECs [3,4]. These assays can
detect tubule formation and length, but cannot investigate
invasion in a three-dimensional matrix. Traditionally, transwell
chambers are used to investigate the role of chemokines
and cytokines in EC invasion and migration, but these cham-
bers have permeable membranes that restrict cancer cell/EC
interactions to soluble factors and are not equipped for dy-
namic monitoring. We therefore designed a magnetic reso-
nance (MR)–compatible assay that has an ability to image
network-like structures, as well as cell motility, both noninva-
sively and longitudinally, without restricting cancer cell/EC
interactions with a semipermeable membrane. Here, we have
characterized this noninvasive MR assay by studying the
time course of EC invasion, migration, and tubulogenesis in
a coculture system containing breast cancer cells and ECs.
Human umbilical vein endothelial cells (HUVECs) were labeled,
by endocytosis, with an intracellular superparamagnetic
iron oxide (SPIO) contrast agent. SPIO particles effectively
shorten the transverse relaxation time (T2) of protons through
susceptibility-induced local magnetic field inhomogeneities,
generating hypointensity contrast in T2-weighted MR images
[5]. Labeled HUVECs were cocultured in a chamber containing
MDA-MB-231 breast cancer cells and an extracellular matrix
(ECM) gel. We demonstrated the suitability of our assay to non-
invasively track the invasion and network formation of HUVECs,
in the presence or absence ofMDA-MB-231 breast cancer cells.
This assay can easily be adapted to study EC response to
perturbations, such as hypoxia or vascular endothelial growth
factor (VEGF) overexpression, and to study a range of con-
ditions involving aberrant angiogenesis, such as cancer, dia-
betic retinopathy, and tissue ischemia.
Methods
Cells and Cell Culture
MDA-MB-231 cells were originally derived from the pleural
effusion of a breast cancer patient [6]. Cells were maintained
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in monolayer culture in RPMI 1640 (Sigma, St. Louis, MO)
supplemented with 9% fetal bovine serum, 90 U/ml penicillin,
and 90 mg/ml streptomycin. HUVECs (Clonetics, Walkers-
ville, MD), were cultured in endothelial growth medium
(EGM-2; Clonetics). All cells were maintained in 5% CO2
and 90% humidity at 37jC, except for 30 minutes or less
during MR experiments.
HUVEC Labeling with Feridex and Poly-L-Lysine (PLL)
Cells were labeled with a commercially available ferum-
oxide suspension Feridex, which has been shown to effec-
tively label cells for T2-weighted MR detection. PLL was used
as a transfection agent for Feridex labeling [7,8]. A labeling
solution was prepared by mixing 2, 9, or 25 mg Feridex/ml
EGM-2 in the presence of either 30, 125, or 375 ng/ml PLL,
respectively. Then, the labeling solution was gently stirred at
50 rpm using a Glas-Col minirotator system (Glas-Col LLC,
Terre Haute, IN). HUVECs were incubated in the labeling
solution at 37jC and 5% CO2 for 24 hours. Cells were col-
lected by trypsinization and resuspended in EGM-2 prior to
seeding on the ECM gel.
Chamber Preparation
Cell invasion assays were housed in Millicell non–cell
culture inserts (Millipore, Billerica, MA) with a 0.4-mm mem-
brane pore. A schematic of chamber construction is shown in
Figure 1. A total of 120 ml of the ECM gel (protein concentra-
tion, 8.8 mg/ml), thawed at 4jC, was placed on the mem-
brane and allowed to polymerize for 30 minutes at 37jC in
a CO2 incubator. MDA-MB-231 cells (1.5  105), suspended
in 100 ml of EGM-2, were seeded in invasion chambers; 100 ml
of EGM-2 was added to control chambers. After 4 hours
of incubation to allow the cancer cells to adhere to the ECM
gel, 100 ml of the ECM gel (diluted 1:2 in DMEM to prevent
meniscus formation) was added to each chamber. The sec-
ond layer of theECMgel was then polymerized for 30minutes
at 37jC. Finally, 1.5  105 of labeled HUVECs in 300 ml of
EGM-2 were seeded in all chambers, approximately 24 hours
prior to magnetic resonance imaging (MRI), allowing for the
attachment and formation of lumen-like structures. The
chambers were maintained in a 24-well tissue culture plate
with 300 ml/well EGM-2 added outside of the chamber. The
chambers were maintained in an incubator at 37jC, 5%CO2,
and 90% humidity, and removed only for brief periods of time
during the MR experiments.
MRI
MR images were obtained on a 500-MHz (11.74-T) wide-
bore MRI system with a Bruker Avance (Bruker BioSpin
GmBH, Rheinstetten, Germany) spectrometer equipped with
triple-axis gradients. The chambers were submerged, under
sterile conditions, in a 15-mm nuclear magnetic resonance
tube containing EGM-2 and then placed within a 23-mm bird-
cage coil for imaging. Coronal and axial images of the cham-
bers were obtained at room temperature using a T2-weighted,
multislice, spin-echo sequence. All chambers were imaged by
MRI for at least two timepoints: 24 and 120hours postseeding.
After MRI, the chambers were returned to the 24-well plate,
and the medium was refreshed in each well and chamber.
T2-weighted MR images were acquired in one scan with a
field-of-view = 1.6 cm, acquisition matrix = 256  256, slice
thickness = 0.5mm, TE = 60milliseconds, and TR = 617milli-
seconds, unless stated otherwise. These T2-weighted MR
images were used to calculate the percent fractional area
of hypointensity. Gray-scale MR images were binarized
using adaptive thresholding, amethod by which the threshold
operator dynamically changes the threshold over the image
to accommodate intensity changes across the image, and the
percent fractional area of hypointensity was calculated
from these binarized images using Image J (National Insti-
tutes of Health, Bethesda, MD). The percent fractional area
of hypointensity in MRI was considered to be proportional to
the number of iron oxide– labeled HUVECs. An increase in
the number of labeled HUVECs in a given layer relates to an
increase in the percent fractional area of hypointensity, which
was used as an index of labeled HUVECs within that layer.
Fluorescence Microscopy
Chambers were incubated in the dark for 30minutes in the
presence of EC-specific antibody CD31 (Serotec, Oxford,
Figure 1. Schematic of an invasion chamber. (1) A total of 120 l of the ECM gel was added and incubated at 37jC for 30 minutes for polymerization. (2) A total of
1.5  105 MDA-MB-231 cells in 100 l of EGM-2 were seeded on the surface of the ECM gel and incubated for 4 hours to allow cells to attach; 100 l of EGM-2
alone was added to the control chambers. (3) A total of 200 l of the ECM gel (diluted 1:2 in DMEM) was added and polymerized within 30 minutes at 37jC. (4) A
total of 1.5  105 labeled HUVECs in 300 l of EGM-2 were seeded and incubated at 37jC for 24 hours to allow for the attachment of HUVECs and the formation of
lumen-like structures.
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UK) at 1:10 dilution in phosphate-buffered saline (PBS). The
chambers were washed thrice with PBS and observed under
a fluorescent microscope.
Phase-Contrast Microscopy
Chambers were monitored with phase-contrast microsco-
py before and after each MRI experiment. All MR experi-
ments were completed by the 120-hour time point. At the end
of the MR experiments, the cells were stained with Prussian
blue to detect the presence of iron. Chambers were washed
in PBS and incubated for 30 minutes in 2% potassium fer-
rocyanide (Perls reagent) and 6% HCl, followed by a sec-
ond wash in PBS. The chambers were then counterstained
for 5 minutes with a nonspecific nuclei stain Nuclear Fast
Red. Phase-contrast images of 15-mm sections of the cham-
ber, sectioned using a cryostat, were also obtained.
Statistical Analysis
Statistical analysis was performed with JMP software (SAS
Institute, Inc., Cary, NC) using a Wilcoxon rank-sum test.
Unless otherwise noted, P < .05 was considered significant.
Results
As shown in Figure 2, both labeled and unlabeled HUVECs
formed nearly identical network structures at matched time
points, demonstrating the absence of any deleterious effect
of Feridex labeling on HUVEC network formation in the
ECM gel.
Figure 3A demonstrates the ability of T2-weighted MRI to
detect Feridex-labeled HUVECs. Three-dimensional MRI re-
vealed lumen-like structures of labeled HUVECs, as shown
in Figure 3, B and C. MDA-MB-231 breast cancer cells
formed a net-like pattern 24 hours postseeding, as observed
by light microscopy (data not shown). In chambers containing
MDA-MB-231 breast cancer cells, the network of HUVECs
Figure 2. Light microscopy images of chambers with HUVECs, showing no
discernable difference in network structure between unlabeled and labeled
HUVECs at 24 and 120 hours postseeding.
Figure 3. (A) Representative axial MR images of two contiguous 0.5-mm-thick
slices containing HUVECs labeled with 9 g/ml Feridex. A lumen-like network
formation of ECs 24 hours postseeding is apparent in these images, which
were obtained using a T2-weighted spin-echo sequence with a field-of-view =
1.6 cm, acquisition matrix = 256  256, TE = 60 milliseconds, TR = 617 milli-
seconds, and number of averages = 2. (B) A three-dimensional reconstructed
image of multislice data showing a lumen-like HUVEC network in the ECM gel
(left). Orthogonal slices in the axial direction provide the ability to dynamically
follow migration, invasion, and network structure through the ECM gel (right).
(C) A three-dimensional reconstructed image from a multislice MR data set,
with volume rendering demonstrating an intricate HUVEC network.
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was well-preserved over the course of the 120-hour ex-
periment, whereas the controls showed a diminished net-
work structure.
Effective labeling of HUVECs was achieved at all
Feridex concentrations (2, 9, and 25 mg/ml), as evident from
the brown intracytoplasmic granules from Feridex or the
presence of blue regions following Prussian blue staining
for iron content.
Representative axial (Figure 4A) and coronal (Figure 4B)
MR images showed an increased presence of HUVECs
in the cancer cell layer between the two time points, as
observed by MRI, whereas in the control chambers without
cancer cells, the HUVECs did not invade significantly through
the ECM gel. The percent fractional area occupied by
HUVECs in the cancer cell seed layer increased over the
course of the experiment (Figure 5, A and B). For ECs la-
beled with 2 mg/ml Feridex, the fractional area of HUVECs
in the cancer cell seed layer increased significantly, from
2.5 ± 1.3% at 24 hours to 5.0 ± 0.9% at 120 hours (mean ±
SD; n = 6, P < .05), whereas no significant change was
observed in controls from 24 hours (1.1 ± 0.6%) to 120 hours
(1.2 ± 0.2%) (mean ± SD; n = 6). For cells labeled with 9 mg/ml
Feridex, the fractional area of HUVECs in the cancer cell
seed layer increased significantly, from 7.1 ± 2.6% at
24 hours to 16.2 ± 3.1% at 120 hours postseeding (mean ±
SD; n = 5, P < .05). There were no significant changes in
fractional area in the corresponding layer in the control
chambers (1.2 ± 1.8% at 24 hours and 2.9 ± 2.3% at 120
hours postseeding) (mean ± SD; n = 4).
The presence of HUVECs in the cancer cell seed layer
was evident from stainingwith endothelial cell–specific CD31
monoclonal antibody (Figure 6A) and with Prussian blue
staining of HUVECs mixed with cancer cells (Figure 6B).
Discussion
Here, we have noninvasively and longitudinally characterized
HUVEC invasion in response to cancer cells. HUVECs grown
in the presence of cancer cells showed a marked increase
in both network formation and cell invasion, compared to
HUVECs grown without cancer cells.
We started with the published labeling concentration of
25 mg Feridex/ml medium [7–9]. We found that cells labeled
with 40% or even 10% of the initial concentration were easily
detected with our high-field microimaging system. A labeling
concentration of 9 mg/ml Feridex was found to be the suit-
able labeling concentration for HUVECs in this study. The
labeling showed no detrimental effect on HUVEC viability
Figure 4. (A) A panel of three axial MR images acquired 24, 72, and 120 hours postseeding. An increased number of HUVECs were detected with time in the layer
containing MDA-MB-231 cancer cells, as evident from hypointense regions in this layer. HUVECs were labeled with 9 g/ml Feridex. The MR images were
obtained using a T2-weighted spin-echo sequence with field-of-view = 1.6 cm, acquisition matrix = 256  256, eight slices of slice thickness = 0.5 mm, TE =
60 milliseconds, TR = 617 milliseconds, and number of averages = 2. (B) Representative coronal MR images of a chamber containing MDA-MB-231 cells
demonstrating the presence of Feridex-labeled HUVECs confined mainly to the upper seed layer 24 hours postseeding (i), with an increased presence of HUVECs
in the cancer cell layer 120 hours postseeding (ii). By comparison, the control chambers showed no invasion of the ECM gel by the HUVECs, 24 hours (iii) and
120 hours postseeding (iv). The images were obtained in a single scan, using a T2-weighted spin-echo sequence with a field-of-view = 1.6 cm, eight slices of slice
thickness = 1 mm, acquisition matrix = 256  256, TE = 60 milliseconds, and TR = 617 milliseconds.
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and tubulogenesis for Feridex concentrations at or below
9 mg/ml, as measured by trypan blue exclusion and as ob-
served by MRI and light microscopy. This is in agreement
with previous studies suggesting no adverse consequences
of cell labeling with PLL Feridex [9,10], except for chondro-
genic differentiation [9,11]. A Feridex labeling concentration
of 25 mg/ml affected network formation, whereas a lower
concentration (2 mg/ml) showed discernable contrast in MR
images, which detected the presence of clusters of HUVECs,
but not the finer structures of the HUVEC network.
An increasing presence of HUVECs was observed in the
MDA-MB-231 cancer cell seed layer at a later time point,
demonstrating the invasion and migration of HUVECs through
the ECM gel toward the cancer cells. Cell migration requires
proteolytic ECM remodeling for the lowering of matrix orga-
nization barriers to migration and then for tissue remodeling
[12]. Proteolytic enzymes, such as urokinase-type plas-
minogen activator and matrix metalloproteinase, secreted
by cancer cells are known to degrade the surrounding
ECM, leading to directional migration of ECs [13,14]. The
presence of a large population of HUVECs in the cancer cell
seed layer, along with ECM gel architecture, indicated that
cancer cells stimulated the HUVECs to invade through the
ECM and to migrate toward the cancer cells, whereas
there was no significant movement of HUVECs through the
ECM gel in the absence of cancer cells. These results were
confirmed by staining with the endothelial-specific mono-
clonal antibody CD31 and with Prussian blue staining for iron
content, which detected HUVECs in the cancer cell seed
layer. Khodarev et al. [15] have observed an increase in the
migration of HUVECs toward U87 human glioma cells, com-
pared to controls, using a collagen I transwell migration
assay. Gene expression profiling of HUVECs, cultured in
the presence of cancer cells, revealed the expression of sev-
eral growth factors (such as transforming growth factor b3
and FGF7) and their receptors. A panel of experiments in
their study suggests that growth factors released by cancer
cells induce autocrine loops in HUVECs, thereby generating
an angiogenic response with increased migration toward
the cancer cells. The data also suggest a role for cancer cells
in the activation of ECs through the formation of paracrine
loops with soluble ligands secreted by the cancer cells. Al-
though paracrine factors secreted by cancer cells most
likely stimulated the invasion and migration of HUVECs in
our study, it is also possible that local hypoxic environments
created within the cancer cells may have acted as a stimu-
lus for EC migration and invasion. This possibility is currently
under investigation. We are also currently determining if the
Figure 5. Fractional area occupied by HUVECs in the cancer cell seed layer
for (A) HUVECs labeled with 2 g/ml Feridex and (B) HUVECs labeled with
9 g/ml Feridex. The fractional area was calculated for T2-weighted MR
images acquired with TE = 60 milliseconds and TR = 617 milliseconds. A
significant increase (P < .05) was detected in the fractional area (mean ± SD)
occupied by HUVECs in the cancer cell layer for chambers containing MDA-
MB-231 breast cancer cells (n = 6 for 2 g/ml Feridex; n = 5 for 9 g/ml
Feridex), whereas no significant change ( P < .05) was observed in the
corresponding layer in the absence of cancer cells (n = 6 for 2 g/ml Feridex;
n = 4 for 9 g/ml Feridex).
Figure 6. The presence of HUVECs in the cancer cell layer detected by the fluorescence microscopy of immunohistochemistry staining with the CD31 monoclonal
antibody (A). The layer in sharp focus is the layer containing MDA-MB-231 cancer cells which the HUVECs invaded. The inset shows a corresponding phase-
contrast light micrograph. The presence of HUVECs in the cancer cell layer was also detected by Prussian blue staining for iron content (B). Staining with Prussian
blue and Nuclear Fast Red (a nonspecific red stain for nuclei) shows the colocalization of iron-labeled ECs and unlabeled MDA-MB-231 cancer cells.
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migration and invasion of ECs is cancer cell–specific in this
system, or if it occurs for nonmalignant cells as well.
In all chambers, HUVECs formed a lumen-like network
24 hours postseeding, in agreement with previous obser-
vations [16,17]. Our data are consistent with previous
studies, which have shown that cell/cell and cell/ECM
interactions stimulate both HUVEC survival and network
formation [18–22]. At the end of 120 hours, network struc-
tures were well-preserved in chambers with cancer cells,
compared to the control chambers where diminished HUVEC
survival and network structure were observed. One possible
explanation is the presence of antiapoptotic signals derived
from the cancer cells, which increased HUVEC survival
[23–28]. The presence of a small population of HUVECs in
the cancer cell layer in the control chambers was probably
attributable to migration and the baseline invasive ability
of ECs due to the presence of some growth factors in the
ECM gel.
In addition, although HUVECs were used as a model of
ECs to validate the assay described in the present study,
the human microvascular endothelium is not well-represented
by HUVECs [29,30]. For instance, Anderson et al. [31] used
iron oxide labeling to show that a population of mouse bone
marrow–derived cells is enriched in endothelial precursor
cells, which incorporate and differentiate into endothelial-like
cells in the tumor vasculature in a glioma model. Our future
studies will use cells that are more representative of the
human tumor neovasculature, such as VEGF-R2–overex-
pressing ECs [32–36] and endothelial precursor cells [37,38].
In conclusion, cell labeling with SPIO, combined with high-
resolution MRI, allowed a noninvasive and dynamic three-
dimensional characterization of EC networks formed in a
three-dimensional ECM gel. Vessel formation, maturation
[39], quiescence [40], and regression depend on the com-
peting effects of growth [41–43] and inhibitory factors, with
survival and proliferation on one hand and apoptosis on the
other hand [2]. Therefore, this assay can be expanded to
study either EC responses to the synergistic effects of these
competing factors, or the roles of a single perturbation such
as hypoxia [13,14,44–48], a chemokine, or a cytokine. We
are currently studying endothelial response to hypoxia and
VEGF overexpression to understand the precise role of
each factor in angiogenesis. Additionally, our ability to obtain
high-resolution three-dimensional MR images may provide
further insights into the remodeling of basement mem-
branes in response to various factors and conditions, such
as upregulation of growth factors and receptor activity [49].
Our assay serves as amodel system for a range of conditions
involving aberrant angiogenesis, such as cancer, rheumatoid
arthritis, diabetic retinopathy, and tissue ischemia. This novel
assay may prove useful in longitudinal high-throughput
studies to determine the efficacy of proangiogenic and anti-
angiogenic drugs.
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